C2 Pharma (C2P), a pharmaceutical group established in 2014 focused on niche active pharmaceutical ingredient (APIs), has expanded its portfolio of APIs and botanical extracts throughout 2020 and will continue pursuing the expansion into 2021. Multiple regulatory filings have been submitted to expand distribution channels globally across China, Taiwan, South Korea, Brazil, and Mexico.
 
“Since announcing our intentions to go through a growth spurt at CPhI Worldwide in 2019 we have been actively working to deliver on these promises with a range of regulatory filings. Our goal is to be a reliable, quality focused partner for ophthalmic pharmaceutical companies”, said Andrew Badrot, chief executive officer, C2 Pharma. “I am proud of our team and what we are accomplishing for our customers. In less than seven years from being founded, C2P has established an API portfolio with over ten US-DMF and CEP filed in addition to all the local filings we are announcing today, and we have been able to maintain operational excellence and expand our portfolio amid the COVID-19 pandemic.”
 
Recent filings include:
 
Atropine Sulfate:
• China C-DMF published December 2020
• Taiwan T-DMF granted in December 2020
 
Atropine (Base):
• US DMF to be filed by March 2021
• CEP filed in December 2020
 
Homatropine Hydrobromide API:
• US DMF filed in April 2020
• CEP filed in April 2020
 
Homatropine Methylbromide:
• Taiwan T-DMF granted in December 2020
 
Digoxin (Micron), manufacturing site Laurus Labs Limited:
• US DMF available for reference as of April 2020
• CEP filed in November 2019
 
Digoxin, manufacturing site Nobilus Ent:
• China C-DMF published in January 2021
• Korea K-DMF filed in October 2020
 
Digoxin (Micron 10), manufacturing site Nobilus Ent:
• US DMF Amended to include Micron 10 grade filed in October 2020
• CEP to be filed in March 2021